MedTrace Logo

Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study

NCT01528514 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2019-09-18

No results posted yet for this study

Summary

It is well-established that myocardial infarction (MI) associated with coronary artery bypass graft surgery (CABG) predicts the poor outcome. Nevertheless, the cardioprotective therapies to limit myocardial injury after CABG are lacking. Previous studies have shown that curcuminoids suppress pro-inflammatory cytokines during cardiopulmonary bypass surgery and decrease the occurrence of cardiomyocytic apoptosis after cardiac ischemia/reperfusion injury in animal models. The investigators aim to evaluate whether curcuminoids prevent MI after CABG, compared to placebo.

Conditions

  • Coronary Artery Bypass Grafting

Interventions

DIETARY_SUPPLEMENT

Curcuminoids

Curcuminoids in capsule form, 4 capsules four times daily (4 grams/day)

OTHER

Placebo

Placebo in capsule form, 4 capsules 4 times/day

Sponsors & Collaborators

  • Wanwarang Wongcharoen, MD.

    lead OTHER

Principal Investigators

  • Wanwarang Wongcharoen, MD · Faculty of Medicine, Chiang Mai University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-09-30
Completion
2012-12-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01528514 on ClinicalTrials.gov